Matt McCall’s out with another high-priced promo letter that promises the potential for huge gains — this time, by finding the stocks that he thinks will benefit from China’s massive increase in health care spending in the years to come. The ad is for his Early Stage Investor, and he claims to be making a […]
The many welcome comments to the Alzheimer’s piece that posted a couple of weeks ago prompt me to supply answers (if I am able to do that), but also set my mind to wandering on the fringes of a number of issues that may be of interest to the Gumshoe constituency. Anavex 2-73 At the […]
When we’re trying to fight against an adversary that is as strong and full of tricks as cancer, what we need to do is look for points of vulnerability – Achilles heels. We all remember, of course, that the mother of Achilles dipped him in the River Styx when he was a tiny boy, […]
I have no idea what’s going to happen in the market today, but perhaps if I spend my time looking into a teaser pitch from a new newsletter I’ll be too busy to obsess over my portfolio and do something dumb during the trade war panic gyrations. Sound good? Want to join me? Great! The […]
What set me off on this rant was the very first comment on the piece that posted on January 31st, “Looking Backward – And a Peek in the Other Direction.” Here’s the comment: “Thanks, Doc. Hope you will comment on the news out of Israel this week: https://www.jpost.com/HEALTH-SCIENCE/A-cure-for-cancer-Israeli-scientists-say-they-think-they-found-one-578939” Naturally, I looked, and what I found […]
Chances are not many of us observed New Year’s Eve with celebratory toasts to the glorious year gone by. Rather, we bid goodbye to 2018 and hoped 2019 would be a better year – for ourselves, our near and dear, our country, and our planet. However, as I wade through the volumes of healthcare-related stuff […]
The plan was for Doc Gumshoe to fix his gaze on the hype around Delta 8 as the ultimate banned cancer cure, which he will definitely get around to. But the volume of comments and queries that “Cancer: The Lay of the Land in 2018” was such that I have little choice but to […]
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
When I last took a look at what was happening in the treatment of migraines, I took careful pains to elucidate the differences between migraines and a plain old bad headache – the fact that migraines affect only one side of the head, and a detailed disquisition on the symptoms that many migraineurs (that’s the […]
No, these bits won’t be about Melania’s kidney ailment nor yet about what Meghan wore for The Wedding. I wish them both luck – they’ll need it!. However, there continue to be developments on the medical and health-care fronts that may matter to us a good deal more than the doings of those ladies. […]
We’ve seen a long stream of earnings reports and other worthwhile bits of data on Real Money Portfolio stocks since I last wrote to you, including some that actually included some interesting news, so prepare for a lot of quick updates…. Medical Properties Trust (MPW) reported another quarter of ho-hum… pretty much met the forecasts, […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. He does not typically write specifically about investments, but does write about publicly traded companies and their drugs, and has agreed to our trading […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]
Newsletter copywriters are no different from other marketers: they will do whatever it takes to get attention by playing off of something or someone that has celebrity or notoriety. In the past that’s meant implying that some big celebrity investor has a connection to a “secret” stock or technique, or that someone high up in […]
This article originally appeared on July 22, 2015, and the bulk of it has not been updated or revised since. The meat of the ad is essentially the same, and if Lichtenfeld really “bet his paycheck” on this stock (which was and is Alnylam) on July 22 he’s so far lost about 65% of that […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He choses his own topics, his words and opinions are his own, and he has agreed to our trading restrictions. You can see his Stock Gumshoe page here.] When I was an undergraduate student, I became a good friend of Michael D., […]
Alzheimer’s Wrap-Up
[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
What Lurks Beyond the “Heartbreak of Psoriasis?”
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe,” writes non-investment articles for us about medical and health topics a couple times a month. He is a medical writer, not a doctor, and his words and thoughts are his own.] Just possibly a tiny few of the Gumshoe faithful may remember that advertising […]
[Ed Note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he sometimes mentions a couple publicly traded companies). His words and opinions are his own. […]
Cancer Care: Current Directions
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
Cancer Care: Where Are We and Where Are We Headed?
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
[ed note: Michael Jorrin, who we like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who writes non-investment articles about medicine and health topics for us once or twice a month. As with all of our guest contributors and columnists, he chooses his own topics and his words are his alone] […]
Dawn of the Planet of the TLOGlodytes!
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own, and he has agreed to our trading restrictions.] Want to see something really cool? A hot video clip from a steamy biotech thriller? Watch this. Better yet, when you pull up the video viewing frame, […]
A Non-Statin Pill That Really Lowers Cholesterol, Blood Pressure and Inflammation without Side Effects Would be a Good Investment, Right?
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
Is This Red-Hot New “Blood Stock” Any Bloody Good as an Investment?
[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]
Is Any Big Pharma Outfit NOT Interested in Buying This Little-Known Biotech?
What’s the commonest reason for admission to hospital of people 65 and over? Mull that question, as it provides context. Think of people you know. At least one probably has this condition. It’s not diabetes. It’s not heart attacks. And it is not infectious. But it kills and lots of people have it. Part II […]
Will PCSK9 Inhibitors Be the Next Blockbusters in Cardiovascular Disease?
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. As always, Michael’s words and opinions are his own.] Lots of analysts and prognosticators give these cholesterol-lowering agents a big thumbs up. The […]
[ed note: Another piece from “Doc Gumshoe” today — Michael Jorrin is not a doctor, he’s a longtime medical writer who we love because he explains diseases, treatments, and health controversies in a way that makes sense. The words and opinions shared below are his alone. If you’re curious about whether rheumatoid arthritis matters to […]
What’s Happening in Cancer Treatment? Are We Making Progress, or Are We Stuck?
Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]
We haven’t tried to sniff out a Louis Navellier pick for quite a while — partly because he hasn’t had a lot of single-stock teaser ads running lately, and partly because, well, they haven’t piqued our interest. But everyone loves the idea of “buy and forget” stocks — it can be fun to be a […]
Comments
$RDUS Long Radius rises after safety of Amgen osteoporosis drug questioned Shares of Radius Health (RDUS) are tradi...
$ABBV $GILD $AMGN - An interesting article from IBD evaluating comparatively three biotech giants "AbbVie Stronger B...
Pre-market actions, 1/6, per IBD at 8:45am In Motion: Amgen, Regeneron, Ionis, Verizon Premarket action was a mixe...
Out at Amgen ($AMGN). Biotech buoyancy doing nothing for shares. Out for slight profit....
We don't discuss Amgen $AMGN much on this site but I follow them. Here's news of another rejection from the FDA. http://...
I put a little Amgen $AMGN in my portfolio today as a trading buy. Earnings have awakened the street to what a powerhous...
$CLCD long. Amgen ($AMGN) and Novartis’ ($NVS) migraine drug erenumab has hit the primary endpoint in a Phase II trial...
Amgen (AMGN) looking mighty fine on cancer front. http://www.cmlviz.com/cmld3b/lite.php?number=1041&app=news&cml_articl...
Interesting Baron's article. Gilead Science, How bad can it get? Email Print smaller Larger By Ben Levisohn ...
Not to blow my own horn too blatantly, but here's what I said about Kite in a Doc Gumshoe posting back in February. I ...
Don’t Buy Gilead’s Headline Gilead Sciences (GILD – NASDAQ) By Bottarelli Research Published Friday, May 01, 20...